{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,25]],"date-time":"2026-02-25T20:13:30Z","timestamp":1772050410257,"version":"3.50.1"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2019,8,15]],"date-time":"2019-08-15T00:00:00Z","timestamp":1565827200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2019,8,15]],"date-time":"2019-08-15T00:00:00Z","timestamp":1565827200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Clin Pharmacol"],"published-print":{"date-parts":[[2019,11]]},"DOI":"10.1007\/s00228-019-02740-y","type":"journal-article","created":{"date-parts":[[2019,8,15]],"date-time":"2019-08-15T23:02:42Z","timestamp":1565910162000},"page":"1593-1598","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Breast cancer and spironolactone: an observational postmarketing study"],"prefix":"10.1007","volume":"75","author":[{"given":"Pierre","family":"Sabatier","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jacques","family":"Amar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fran\u00e7ois","family":"Montastruc","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vanessa","family":"Rousseau","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Leila","family":"Chebane","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B\u00e9atrice","family":"Bouhanick","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6341-6001","authenticated-orcid":false,"given":"Jean-Louis","family":"Montastruc","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,8,15]]},"reference":[{"key":"2740_CR1","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1038\/sj.jhh.1002075","volume":"20","author":"JA Largent","year":"2006","unstructured":"Largent JA, McEligot AJ, Ziogas A, Reid C, Hess J, Leighton N, Peel D, Anton-Culver H (2006) Hypertension, diuretics and breast cancer risk. J Hum Hypertens 20:727\u2013732","journal-title":"J Hum Hypertens"},{"key":"2740_CR2","doi-asserted-by":"publisher","first-page":"e0159672","DOI":"10.1371\/journal.pone.0159672","volume":"11","author":"I G\u00f3mez-Acebo","year":"2016","unstructured":"G\u00f3mez-Acebo I, Dierssen-Sotos T, Palazuelos C, P\u00e9rez-G\u00f3mez B, Lope V, Tusquets I, Alonso MH, Moreno V, Amiano P, Molina de la Torre AJ, Barricarte A, Tardon A, Camacho A, Peiro-Perez R, Marcos-Gragera R, Mu\u00f1oz M, Michelena-Echeveste MJ, Ortega Valin L, Guevara M, Casta\u00f1o-Vinyals G, Aragon\u00e9s N, Kogevinas M, Poll\u00e1n M, Llorca J, G\u00f3mez-Acebo I, Dierssen-Sotos T, Palazuelos C, P\u00e9rez-G\u00f3mez B, Lope V, Tusquets I, Alonso MH, Moreno V, Amiano P, de la Torre AJ M, Barricarte A, Tardon A, Camacho A, Peiro-Perez R, Marcos-Gragera R, Mu\u00f1oz M, Michelena-Echeveste MJ, Ortega Valin L, Guevara M, Casta\u00f1o-Vinyals G, Aragon\u00e9s N, Kogevinas M, Poll\u00e1n M, Llorca J (2016) The use of antihypertensive medication and the risk of breast cancer in a case-control study in a Spanish population: the MCC-Spain study. PLoS One 11:e0159672","journal-title":"PLoS One"},{"key":"2740_CR3","doi-asserted-by":"publisher","first-page":"1504","DOI":"10.1002\/cncr.11663","volume":"98","author":"CI Li","year":"2003","unstructured":"Li CI, Malone KE, Weiss NS, Boudreau DM, Cushing-Haugen KL, Daling JR (2003) Relation between use of antihypertensive medications and risk of breast carcinoma among women ages 65-79 years. Cancer 98:1504\u20131513","journal-title":"Cancer"},{"key":"2740_CR4","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1080\/10641963.2017.1288736","volume":"40","author":"Y Zhao","year":"2018","unstructured":"Zhao Y, Wang Q, Zhao X, Meng H, Yu J (2018) Effect of antihypertensive drugs on breast cancer risk in female hypertensive patients: evidence from observational studies. Clin Exp Hypertens 40:22\u201327","journal-title":"Clin Exp Hypertens"},{"key":"2740_CR5","first-page":"445","volume-title":"Goodman and Gilman\u2019s the pharmacological basis of therapeutics","author":"EK Jackson","year":"2018","unstructured":"Jackson EK (2018) Drugs affecting renal excretory function. In: Brunton LL, Hilal-Dandan R, Knollmann BJ (eds) Goodman and Gilman\u2019s the pharmacological basis of therapeutics, 13th edn. New York, Mc Graw Hill, pp 445\u2013470","edition":"13"},{"key":"2740_CR6","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1111\/j.1365-2265.1978.tb01510.x","volume":"9","author":"A Miyatake","year":"1978","unstructured":"Miyatake A, Noma K, Nakao K, Morimoto Y, Yamamura Y (1978) Increased serum oestrone and oestradiol following spironolactone administration in hypertensive men. Clin Endocrinol 9:523\u2013533","journal-title":"Clin Endocrinol"},{"key":"2740_CR7","doi-asserted-by":"publisher","first-page":"870","DOI":"10.1016\/j.canep.2013.10.004","volume":"37","author":"RJ Biggar","year":"2013","unstructured":"Biggar RJ, Andersen EW, Wohlfahrt J, Melbye M (2013) Spironolactone use and the risk of breast and gynecologic cancers. Cancer Epidemiol 37:870\u2013875","journal-title":"Cancer Epidemiol"},{"key":"2740_CR8","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.e4447","volume":"345","author":"IS Mackenzie","year":"2012","unstructured":"Mackenzie IS, Macdonald TM, Thompson A, Morant S, Wei L (2012) Spironolactone and risk of incident breast cancer in women older than 55 years: retrospective, matched cohort study. BMJ 345:e4447","journal-title":"BMJ"},{"key":"2740_CR9","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1111\/bcp.13152","volume":"83","author":"IS Mackenzie","year":"2017","unstructured":"Mackenzie IS, Morant SV, Wei L, Thompson AM, MacDonald TM (2017) Spironolactone use and risk of incident cancers: a retrospective, matched cohort study. Br J Clin Pharmacol 83:653\u2013663","journal-title":"Br J Clin Pharmacol"},{"key":"2740_CR10","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1111\/j.1472-8206.2007.00552.x","volume":"22","author":"A Bate","year":"2008","unstructured":"Bate A, Lindquist M, Edwards IR (2008) The application of knowledge discovery in databases to post-marketing drug safety: example of the WHO database. Fundam Clin Pharmacol 22:127\u2013140","journal-title":"Fundam Clin Pharmacol"},{"key":"2740_CR11","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1007\/s40264-013-0131-x","volume":"37","author":"T Bergvall","year":"2014","unstructured":"Bergvall T, Nor\u00e9n GN, Lindquist M (2014) VigiGrade: a tool to identify well-documented individual case reports and highlight systematic data quality issues. Drug Saf 37:65\u201377","journal-title":"Drug Saf"},{"key":"2740_CR12","doi-asserted-by":"publisher","first-page":"1255","DOI":"10.1016\/S0140-6736(00)02799-9","volume":"356","author":"IR Edwards","year":"2000","unstructured":"Edwards IR, Aronson JK (2000) Adverse drug reactions: definitions, diagnosis and management. Lancet 356:1255\u20131259","journal-title":"Lancet"},{"key":"2740_CR13","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1111\/j.1365-2125.2011.04037.x","volume":"72","author":"JL Montastruc","year":"2011","unstructured":"Montastruc JL, Sommet A, Bagheri H, Lapeyre-Mestre M (2011) Benefits and strengths of the disproportionality analysis for identification of adverse drug reactions in a pharmacovigilance database. Br J Clin Pharmacol 72:905\u2013908","journal-title":"Br J Clin Pharmacol"},{"key":"2740_CR14","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1016\/j.therap.2019.01.006","volume":"74","author":"JL Faillie","year":"2019","unstructured":"Faillie JL (2019) Case-non case studies: principles, methods, bias and interpretation. Therapie 74:225\u2013232","journal-title":"Therapie"},{"key":"2740_CR15","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1016\/S1470-2045(00)00254-0","volume":"2","author":"TJ Key","year":"2001","unstructured":"Key TJ, Verkasalo PK, Banks E (2001) Epidemiology of breast cancer. Lancet Oncol 2:133\u2013140","journal-title":"Lancet Oncol"},{"key":"2740_CR16","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1016\/j.critrevonc.2016.02.017","volume":"101","author":"IS Fentiman","year":"2016","unstructured":"Fentiman IS (2016) Male breast cancer is not congruent with the female disease. Crit Rev Oncol Hematol 101:119\u2013124","journal-title":"Crit Rev Oncol Hematol"},{"key":"2740_CR17","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1053\/j.seminoncol.2009.03.001","volume":"36","author":"CK Anders","year":"2009","unstructured":"Anders CK, Johnson R, Litton J, Phillips M, Bleyer A (2009) Breast cancer before age 40 years. Semin Oncol 36:237\u2013249","journal-title":"Semin Oncol"},{"issue":"Suppl 1","key":"2740_CR18","first-page":"S2","volume":"5","author":"HA Assi","year":"2013","unstructured":"Assi HA, Khoury KE, Dbouk H, Khalil LE, Mouhieddine TH, El Saghir NS (2013) Epidemiology and prognosis of breast cancer in young women. J Thorac Dis 5(Suppl 1):S2\u2013S8","journal-title":"J Thorac Dis"},{"key":"2740_CR19","unstructured":"(1975) Editorial: reserpine and breast cancer. Can Med Assoc J 112:129"},{"key":"2740_CR20","doi-asserted-by":"publisher","first-page":"1343","DOI":"10.1053\/euhj.2001.2729","volume":"22","author":"E Grossman","year":"2001","unstructured":"Grossman E, Messerli FH, Goldbourt U (2001) Antihypertensive therapy and the risk of malignancies. Eur Heart J 22:1343\u20131352","journal-title":"Eur Heart J"},{"key":"2740_CR21","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1007\/BF03261981","volume":"35","author":"A Pariente","year":"2012","unstructured":"Pariente A, Avillach P, Salvo F, Thiessard F, Miremont-Salam\u00e9 G, Fourrier-Reglat A, Haramburu F, B\u00e9gaud B, Moore N, Association Fran\u00e7aise des Centres R\u00e9gionaux de Pharmacovigilance (CRPV) (2012) Effect of competition bias in safety signal generation: analysis of a research database of spontaneous reports in France. Drug Saf 35:855\u2013864","journal-title":"Drug Saf"},{"key":"2740_CR22","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1016\/j.therap.2016.09.020","volume":"72","author":"J Bezin","year":"2017","unstructured":"Bezin J, Bosco-Levy P, Pariente A (2017) False-positive results in pharmacoepidemiology and pharmacovigilance. Therapie 72:415\u2013420","journal-title":"Therapie"},{"key":"2740_CR23","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1016\/j.therap.2016.02.029","volume":"71","author":"T Vial","year":"2016","unstructured":"Vial T (2016) French pharmacovigilance: missions, organization and perspectives. Therapie 71:143\u2013150","journal-title":"Therapie"},{"issue":"7922","key":"2740_CR24","doi-asserted-by":"publisher","first-page":"1428","DOI":"10.1016\/S0140-6736(75)92645-8","volume":"1","author":"SD Loube","year":"1975","unstructured":"Loube SD, Quirk RA (1975) Breast cancer associated with administration of spironolactone. Lancet 1(7922):1428\u20131429","journal-title":"Lancet"},{"key":"2740_CR25","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1016\/0190-9622(91)70034-Y","volume":"24","author":"JC Shaw","year":"1991","unstructured":"Shaw JC (1991) Spironolactone in dermatologic therapy. J Am Acad Dermatol 24:236\u2013243","journal-title":"J Am Acad Dermatol"},{"key":"2740_CR26","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1016\/S0190-9622(08)80535-X","volume":"26","author":"WJ Cunliffe","year":"1992","unstructured":"Cunliffe WJ (1992) Spironolactone in dermatology. J Am Acad Dermatol 26:137\u2013138","journal-title":"J Am Acad Dermatol"},{"key":"2740_CR27","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1016\/j.therap.2018.08.001","volume":"74","author":"JL Montastruc","year":"2019","unstructured":"Montastruc JL, Benevent J, Montastruc F, Bagheri H, Despas F, Lapeyre-Mestre M, Sommet A (2019) What is pharmacoepidemiology? Definition, methods, interest and clinical applications. Therapie 74:169\u2013174","journal-title":"Therapie"},{"key":"2740_CR28","doi-asserted-by":"publisher","first-page":"k4880","DOI":"10.1136\/bmj.k4880","volume":"363","author":"D Abrahami","year":"2018","unstructured":"Abrahami D, Douros A, Yin H, Yu OH, Faillie JL, Montastruc F, Platt RW, Bouganim N, Azoulay L (2018) Incretin based drugs and risk of cholangiocarcinoma among patients with type 2 diabetes: population based cohort study. BMJ. 363:k4880. \nhttps:\/\/doi.org\/10.1136\/bmj.k4880","journal-title":"BMJ."},{"key":"2740_CR29","doi-asserted-by":"publisher","first-page":"385","DOI":"10.2165\/00002018-200629050-00003","volume":"29","author":"L Hazell","year":"2006","unstructured":"Hazell L, Shakir SA (2006) Under-reporting of adverse drug reactions: a systematic review. Drug Saf 29:385\u2013396","journal-title":"Drug Saf"}],"container-title":["European Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-019-02740-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00228-019-02740-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-019-02740-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,8,13]],"date-time":"2020-08-13T23:22:02Z","timestamp":1597360922000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00228-019-02740-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,8,15]]},"references-count":29,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2019,11]]}},"alternative-id":["2740"],"URL":"https:\/\/doi.org\/10.1007\/s00228-019-02740-y","relation":{},"ISSN":["0031-6970","1432-1041"],"issn-type":[{"value":"0031-6970","type":"print"},{"value":"1432-1041","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,8,15]]},"assertion":[{"value":"26 April 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 August 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 August 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"JA is a co-founder, shareholder, and consultant of VAIOMER (), a biotech company which specializes in tissue and blood microbiota analyses. He is at the editorial board of \u201cLa revue des microbiotes,\u201d a journal sponsored by PiLeJe Laboratories. He received consultancy fees or support to attend meetings or grants for research from almost all companies marketing antihypertensive drugs. BB received consultancy fees or supports to attend meeting from Astra-Zeneca, Bouchara-Recordati, Lilly, Novartis, Novo-Nordisk, Sanofi, Servier, Takeda, and MSD, but she had no competing interest concerning this article. The other authors have no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"The opinions and conclusions in this study are not necessarily those of the various centers or of the WHO or ANSM (Agence Nationale de S\u00e9curit\u00e9 du M\u00e9dicament et des produits de sant\u00e9, France).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclaimer"}}]}}